Metastatic Pancreatic Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Metastatic Pancreatic Cancer – Pipeline Review, H2 2016’, provides an overview of the Metastatic Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer

The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects

The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Metastatic Pancreatic Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Aduro BioTech, Inc.

ArQule, Inc.

Array BioPharma Inc.

AstraZeneca Plc

Axcentua Pharmaceuticals AB

Berg LLC

BioLineRx, Ltd.

Bionomics Limited

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Clovis Oncology, Inc.

Cornerstone Pharmaceuticals, Inc.

CrystalGenomics, Inc.

CTI BioPharma Corp.

CytRx Corporation

Daiichi Sankyo Company, Limited

Eleison Pharmaceuticals LLC

Eli Lilly and Company

Ensol Biosciences Inc.

Erytech Pharma SA

F. Hoffmann-La Roche Ltd.

Fountain Biopharma Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Immodulon Therapeutics Ltd.

Incyte Corporation

MabVax Therapeutics Holdings, Inc.

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

NanoCarrier Co., Ltd.

NantKwest, Inc.

Natco Pharma Limited

NewLink Genetics Corporation

Novartis AG

Oncolytics Biotech Inc.

Oncovir, Inc.

Oryx GmbH & Co. KG

Pfizer Inc.

Pharmacyclics, Inc.

Phoenix Biotechnology, Inc.

Precision Biologics, Inc.

Rexahn Pharmaceuticals, Inc.

Silence Therapeutics Plc

Targovax ASA

Tiltan Pharma Ltd.

Tocagen Inc.

Zeria Pharmaceutical Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Metastatic Pancreatic Cancer Overview 10

Therapeutics Development 11

Pipeline Products for Metastatic Pancreatic Cancer - Overview 11

Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 12

Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 13

Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 17

Metastatic Pancreatic Cancer - Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Metastatic Pancreatic Cancer - Products under Development by Companies 21

Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 26

Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 27

AbbVie Inc 27

Aduro BioTech, Inc. 28

ArQule, Inc. 29

Array BioPharma Inc. 30

AstraZeneca Plc 31

Axcentua Pharmaceuticals AB 32

Berg LLC 33

BioLineRx, Ltd. 34

Bionomics Limited 35

Boehringer Ingelheim GmbH 36

Boston Biomedical, Inc. 37

Bristol-Myers Squibb Company 38

Celgene Corporation 39

Clovis Oncology, Inc. 40

Cornerstone Pharmaceuticals, Inc. 41

CrystalGenomics, Inc. 42

CTI BioPharma Corp. 43

CytRx Corporation 44

Daiichi Sankyo Company, Limited 45

Eleison Pharmaceuticals LLC 46

Eli Lilly and Company 47

Ensol Biosciences Inc. 48

Erytech Pharma SA 49

F. Hoffmann-La Roche Ltd. 50

Fountain Biopharma Inc. 51

Gilead Sciences, Inc. 52

GlaxoSmithKline Plc 53

Immodulon Therapeutics Ltd. 54

Incyte Corporation 55

MabVax Therapeutics Holdings, Inc. 56

Merck & Co., Inc. 57

Merrimack Pharmaceuticals, Inc. 58

NanoCarrier Co., Ltd. 59

NantKwest, Inc. 60

Natco Pharma Limited 61

NewLink Genetics Corporation 62

Novartis AG 63

Oncolytics Biotech Inc. 64

Oncovir, Inc. 65

Oryx GmbH & Co. KG 66

Pfizer Inc. 67

Pharmacyclics, Inc. 68

Phoenix Biotechnology, Inc. 69

Precision Biologics, Inc. 70

Rexahn Pharmaceuticals, Inc. 71

Silence Therapeutics Plc 72

Targovax ASA 73

Tiltan Pharma Ltd. 74

Tocagen Inc. 75

Zeria Pharmaceutical Co., Ltd. 76

Metastatic Pancreatic Cancer - Therapeutics Assessment 77

Assessment by Monotherapy Products 77

Assessment by Combination Products 78

Assessment by Target 79

Assessment by Mechanism of Action 85

Assessment by Route of Administration 91

Assessment by Molecule Type 93

Drug Profiles 95

(curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile 95

5B1-ADC - Drug Profile 96

acalabrutinib - Drug Profile 97

aldoxorubicin hydrochloride - Drug Profile 100

alpelisib - Drug Profile 114

ARQ-761 - Drug Profile 117

asparaginase - Drug Profile 118

atezolizumab - Drug Profile 125

Atu-027 - Drug Profile 138

avasimibe - Drug Profile 142

AXP-10711 - Drug Profile 143

BI-853520 - Drug Profile 145

binimetinib - Drug Profile 146

BL-8040 - Drug Profile 153

BNC-101 - Drug Profile 163

Cellular Immunotherapy for Oncology - Drug Profile 166

Cellular Immunotherapy for Oncology - Drug Profile 167

Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile 168

ceritinib - Drug Profile 170

CG-200745 - Drug Profile 175

Charis-1000 - Drug Profile 176

CIM-1 - Drug Profile 177

cisplatin - Drug Profile 178

CPI-613 - Drug Profile 180

dacomitinib - Drug Profile 185

ensituximab - Drug Profile 188

FB-704A - Drug Profile 192

flucytosine ER + vocimagene amiretrorepvec - Drug Profile 193

galunisertib - Drug Profile 200

glufosfamide - Drug Profile 203

GS-5745 - Drug Profile 205

GSK-2256098 - Drug Profile 207

haNK Program - Drug Profile 209

HuMab-5B1 - Drug Profile 210

ibrutinib - Drug Profile 213

IMM-101 - Drug Profile 238

INCB-52793 - Drug Profile 240

indoximod - Drug Profile 241

irinotecan hydrochloride - Drug Profile 246

istiratumab - Drug Profile 257

lapatinib ditosylate - Drug Profile 259

LCL-161 - Drug Profile 264

MesoCART - Drug Profile 266

MK-2206 - Drug Profile 267

MK-2206 + selumetinib sulfate - Drug Profile 270

Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 271

MVT-1075 - Drug Profile 273

napabucasin - Drug Profile 274

nimotuzumab - Drug Profile 280

NRCAN-019 - Drug Profile 284

olaparib - Drug Profile 286

paclitaxel albumin bound - Drug Profile 295

palbociclib - Drug Profile 303

Parvoryx - Drug Profile 313

PBI-05204 - Drug Profile 315

PCI-27483 - Drug Profile 317

pelareorep - Drug Profile 319

PLX-7486 - Drug Profile 333

Poly-ICLC - Drug Profile 334

PRI-724 - Drug Profile 337

RG-7876 - Drug Profile 339

ribociclib succinate - Drug Profile 340

rottlerin - Drug Profile 344

rucaparib camsylate - Drug Profile 345

RX-0201 - Drug Profile 352

SGT-53 - Drug Profile 356

Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile 358

sonidegib phosphate - Drug Profile 359

TG-01 - Drug Profile 363

TL-118 - Drug Profile 365

tosedostat - Drug Profile 367

trametinib dimethyl sulfoxide - Drug Profile 372

ubidecarenone - Drug Profile 376

ulixertinib - Drug Profile 378

ulocuplumab - Drug Profile 379

Vaccine for Oncology - Drug Profile 381

veliparib - Drug Profile 382

Z-360 - Drug Profile 388

Metastatic Pancreatic Cancer - Dormant Projects 389

Metastatic Pancreatic Cancer - Discontinued Products 394

Metastatic Pancreatic Cancer - Product Development Milestones 397

Featured News & Press Releases 397

Appendix 409

Methodology 409

Coverage 409

Secondary Research 409

Primary Research 409

Expert Panel Validation 409

Contact Us 409

Disclaimer 410

List of Tables

List of Tables

Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016 17

Number of Products under Development for Metastatic Pancreatic Cancer – Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Development by Companies, H2 2016 (Contd..1) 20

Number of Products under Development by Companies, H2 2016 (Contd..2) 21

Number of Products under Development by Companies, H2 2016 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H2 2016 23

Comparative Analysis by Late Stage Development, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 25

Comparative Analysis by Early Stage Development, H2 2016 26

Products under Development by Companies, H2 2016 27

Products under Development by Companies, H2 2016 (Contd..1) 28

Products under Development by Companies, H2 2016 (Contd..2) 29

Products under Development by Companies, H2 2016 (Contd..3) 30

Products under Development by Companies, H2 2016 (Contd..4) 31

Products under Investigation by Universities/Institutes, H2 2016 32

Metastatic Pancreatic Cancer – Pipeline by AbbVie Inc, H2 2016 33

Metastatic Pancreatic Cancer – Pipeline by Aduro BioTech, Inc., H2 2016 34

Metastatic Pancreatic Cancer – Pipeline by ArQule, Inc., H2 2016 35

Metastatic Pancreatic Cancer – Pipeline by Array BioPharma Inc., H2 2016 36

Metastatic Pancreatic Cancer – Pipeline by AstraZeneca Plc, H2 2016 37

Metastatic Pancreatic Cancer – Pipeline by Axcentua Pharmaceuticals AB, H2 2016 38

Metastatic Pancreatic Cancer – Pipeline by Berg LLC, H2 2016 39

Metastatic Pancreatic Cancer – Pipeline by BioLineRx, Ltd., H2 2016 40

Metastatic Pancreatic Cancer – Pipeline by Bionomics Limited, H2 2016 41

Metastatic Pancreatic Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 42

Metastatic Pancreatic Cancer – Pipeline by Boston Biomedical, Inc., H2 2016 43

Metastatic Pancreatic Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 44

Metastatic Pancreatic Cancer – Pipeline by Celgene Corporation, H2 2016 45

Metastatic Pancreatic Cancer – Pipeline by Clovis Oncology, Inc., H2 2016 46

Metastatic Pancreatic Cancer – Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016 47

Metastatic Pancreatic Cancer – Pipeline by CrystalGenomics, Inc., H2 2016 48

Metastatic Pancreatic Cancer – Pipeline by CTI BioPharma Corp., H2 2016 49

Metastatic Pancreatic Cancer – Pipeline by CytRx Corporation, H2 2016 50

Metastatic Pancreatic Cancer – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 51

Metastatic Pancreatic Cancer – Pipeline by Eleison Pharmaceuticals LLC, H2 2016 52

Metastatic Pancreatic Cancer – Pipeline by Eli Lilly and Company, H2 2016 53

Metastatic Pancreatic Cancer – Pipeline by Ensol Biosciences Inc., H2 2016 54

Metastatic Pancreatic Cancer – Pipeline by Erytech Pharma SA, H2 2016 55

Metastatic Pancreatic Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 56

Metastatic Pancreatic Cancer – Pipeline by Fountain Biopharma Inc., H2 2016 57

Metastatic Pancreatic Cancer – Pipeline by Gilead Sciences, Inc., H2 2016 58

Metastatic Pancreatic Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 59

Metastatic Pancreatic Cancer – Pipeline by Immodulon Therapeutics Ltd., H2 2016 60

Metastatic Pancreatic Cancer – Pipeline by Incyte Corporation, H2 2016 61

Metastatic Pancreatic Cancer – Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016 62

Metastatic Pancreatic Cancer – Pipeline by Merck & Co., Inc., H2 2016 63

Metastatic Pancreatic Cancer – Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 64

Metastatic Pancreatic Cancer – Pipeline by NanoCarrier Co., Ltd., H2 2016 65

Metastatic Pancreatic Cancer – Pipeline by NantKwest, Inc., H2 2016 66

Metastatic Pancreatic Cancer – Pipeline by Natco Pharma Limited, H2 2016 67

Metastatic Pancreatic Cancer – Pipeline by NewLink Genetics Corporation, H2 2016 68

Metastatic Pancreatic Cancer – Pipeline by Novartis AG, H2 2016 69

Metastatic Pancreatic Cancer – Pipeline by Oncolytics Biotech Inc., H2 2016 70

Metastatic Pancreatic Cancer – Pipeline by Oncovir, Inc., H2 2016 71

Metastatic Pancreatic Cancer – Pipeline by Oryx GmbH & Co. KG, H2 2016 72

Metastatic Pancreatic Cancer – Pipeline by Pfizer Inc., H2 2016 73

Metastatic Pancreatic Cancer – Pipeline by Pharmacyclics, Inc., H2 2016 74

Metastatic Pancreatic Cancer – Pipeline by Phoenix Biotechnology, Inc., H2 2016 75

Metastatic Pancreatic Cancer – Pipeline by Precision Biologics, Inc., H2 2016 76

Metastatic Pancreatic Cancer – Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 77

Metastatic Pancreatic Cancer – Pipeline by Silence Therapeutics Plc, H2 2016 78

Metastatic Pancreatic Cancer – Pipeline by Targovax ASA, H2 2016 79

Metastatic Pancreatic Cancer – Pipeline by Tiltan Pharma Ltd., H2 2016 80

Metastatic Pancreatic Cancer – Pipeline by Tocagen Inc., H2 2016 81

Metastatic Pancreatic Cancer – Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2016 82

Assessment by Monotherapy Products, H2 2016 83

Assessment by Combination Products, H2 2016 84

Number of Products by Stage and Target, H2 2016 86

Number of Products by Stage and Mechanism of Action, H2 2016 92

Number of Products by Stage and Route of Administration, H2 2016 98

Number of Products by Stage and Molecule Type, H2 2016 100

Metastatic Pancreatic Cancer – Dormant Projects, H2 2016 395

Metastatic Pancreatic Cancer – Dormant Projects (Contd..1), H2 2016 396

Metastatic Pancreatic Cancer – Dormant Projects (Contd..2), H2 2016 397

Metastatic Pancreatic Cancer – Dormant Projects (Contd..3), H2 2016 398

Metastatic Pancreatic Cancer – Dormant Projects (Contd..4), H2 2016 399

Metastatic Pancreatic Cancer – Discontinued Products, H2 2016 400

Metastatic Pancreatic Cancer – Discontinued Products (Contd..1), H2 2016 401

Metastatic Pancreatic Cancer – Discontinued Products (Contd..2), H2 2016 402

List of Figures

List of Figures

Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016 17

Number of Products under Development for Metastatic Pancreatic Cancer – Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Investigation by Universities/Institutes, H2 2016 23

Comparative Analysis by Late Stage Development, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 25

Comparative Analysis by Early Stage Products, H2 2016 26

Assessment by Monotherapy Products, H2 2016 83

Assessment by Combination Products, H2 2016 84

Number of Products by Top 10 Targets, H2 2016 85

Number of Products by Stage and Top 10 Targets, H2 2016 85

Number of Products by Top 10 Mechanism of Actions, H2 2016 91

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 91

Number of Products by Top 10 Routes of Administration, H2 2016 97

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 97

Number of Products by Top 10 Molecule Types, H2 2016 99

Number of Products by Stage and Top 10 Molecule Types, H2 2016 99

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports